The approved pills changed the maths
Two oral GLP-1s were approved either side of the new year, both starting at $149 a month. That undercuts a large part of the compounded market.
Updated 2026-09-18
How we are paid: one company on this page — Coreage Rx — pays us a commission if you sign up through our link. It does not buy a better score, a higher position, or the removal of a single criticism. Our rating method and full disclosure are both public.
The whole argument for compounded GLP-1s was price. Two FDA-approved pills have now largely taken that argument away, and a lot of review sites have not caught up.
Both start at $149 a month self-pay. That is more than the cheapest compounded programmes — Ozari Health is $86 and Trimi is $125 — but it is less than the majority of what we track, and it buys a product the FDA has actually reviewed.
Wegovy pill (oral semaglutide)
Approved late December 2025, launched in the US on 5 January 2026. The first oral GLP-1 approved for weight management — the same active ingredient as the Wegovy injection, taken as a daily tablet.
Self-pay from $149/month for the 1.5 mg starting dose. The 4 mg dose was offered at $149/month through 15 April 2026 and $199/month after, with the highest doses around $299/month.
Available through LillyDirect-style manufacturer channels and telehealth partners including Ro, GoodRx Care Direct and Walgreens.
Foundayo (orforglipron)
FDA approved 1 April 2026. The first oral small-molecule, non-peptide GLP-1 receptor agonist approved for weight management. Unlike oral semaglutide it is not a peptide, so it has no food-and-water timing restrictions of the same kind.
Self-pay from $149/month for the lowest 0.8 mg dose, about $199/month at 2.5 mg, and roughly $299-$349/month at higher doses.
Self-pay through LillyDirect, with telehealth partners including Ro.
How they compare with what we normally cover
| Option | From | Form | FDA-approved? |
|---|---|---|---|
| Wegovy pill (oral semaglutide) | $149/mo | Daily tablet | Yes |
| Foundayo (orforglipron) | $149/mo | Daily tablet | Yes |
| Cheapest compounded semaglutide (Ozari Health) | $86/mo | Weekly injection | No |
| Cheapest compounded tirzepatide (Trimi) | $125/mo | Weekly injection | No |
| Typical compounded programme | $189–$449/mo | Weekly injection | No |
| Wegovy injection, self-pay | $199 then $349/mo | Weekly injection | Yes |
Worth knowing. What this does not mean. A pill is not automatically better than an injection. Oral semaglutide has strict instructions about taking it on an empty stomach with a small sip of water and waiting before eating — get that wrong and it underperforms. And the trial weight-loss figures for injectable tirzepatide remain the highest of any of these options.
Who should actually consider switching
- Anyone paying more than about $200 a month for a compounded injection. You are now paying a premium for a non-approved product, which is a strange place to be.
- Anyone who never wanted to inject. This is the obvious one — a genuine approved alternative now exists at a sane price.
- Anyone uneasy about the compounding rules. The 2026 regulatory direction is not friendly to compounded GLP-1s; see is compounded still legal.
- Medicare beneficiaries. From July 2026 you may be able to get an approved GLP-1 for $50 a month — see the Medicare programme.
Who probably should not
If you are already on Trimi or Ozari Health at under $130 a month, tolerating it well and getting results, the approved pills cost more. That is a real reason to stay put. The comparison changes if your programme raises prices or your dose pushes you into a higher tier.
Whichever direction you are considering, it is a conversation with a prescriber rather than a purchase decision. Both drugs have contraindications, and switching between them is not simply swapping one box for another.
Read next
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- The dose ladder
Why you start low, how fast you climb, and why the price of each rung matters more than people expect.
- Is compounded medication still legal?
Yes, but much more narrowly than in 2024. What changed, and the five questions to ask before you start.
- Tirzepatide or semaglutide?
One produced larger average weight loss in a head-to-head trial. The other is gentler on the wallet and, for some people, on the stomach.
- The cheapest weekly shots
Every programme sorted on what leaves your account each month, with membership fees counted and teaser rates ignored.